While clinical performance is important in driving a product’s success in migraine, the overriding differentiation between products, and the CGRP inhibitors in particular, is market access. The CGRP biologics used for migraine prophylaxis are not highly differentiated based on efficacy, and so physicians typically choose brands based on patients’ insurance coverage or those which have more convenient formulations. In the current market, this has posed a high barrier for the newest entrants such as Vyepti (eptinezumab), but developers will continue to negotiate for better formulary placements, which will expand coverage over time. 

This Datamonitor Healthcare report contains a Disease Analysis module.